Role of Biochemical Inflammatory Markers in Patients with Chemotherapy-Induced Neutropenia

YuN Dubinina1, VO Sarzhevskii2, VYa Melnichenko2

1 Oncology and Hematology Outpatient Clinic, 2 bld. 1 Molodogvardeiskaya str., Moscow, Russian Federation, 121467

2 NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203

For correspondence: Yuliya Nikolaevna Dubinina, 2 bld. 1 Molodogvardeiskaya str., Moscow, Russian Federation, 121467; Tel.: +7(499)112-25-04; e-mail:

For citation: Dubinina YuN, Sarzhevskii VO, Melnichenko VYa. Role of Biochemical Inflammatory Markers in Patients with Chemotherapy-Induced Neutropenia. Clinical oncohematology. 2019;12(4):461–7 (In Russ).

DOI: 10.21320/2500-2139-2019-12-4-461-467


The growing number of autologous and allogeneic transplantations of bone marrow and hematopoietic stem cells as well as their technological effectiveness give rise to drug antineoplastic therapies with increased toxicity leading to development of complications. The most serious among this sort of complications are infections. Probability of infections in patients with chemotherapy-induced neutropenia reaches 90 %. In this context the search for an optimal marker of infectious complications becomes more and more important. The present review deals with basic biochemical inflammatory markers and the analysis of trials assessing diagnostic and prognostic value of C-reactive protein, procalcitonin, and presepsin.

Keywords: sepsis, autologous bone marrow transplantation, allogeneic bone marrow transplantation, chemotherapy, infection, procalcitonin, presepsin, C-reactive protein.

Received: May 7, 2019

Accepted: September 11, 2019

Read in PDF


  1. Passweg JR, Baldomero H, Bade P, et al. Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2018;53(9):1139–48. doi: 10.1038/s41409-018-0153-1.

  2. Ochs L, Shu XO, Miller J, et al. Late infections after allogeneic bone marrow transplantation: comparison of incidence in related and unrelated donor transplant recipients. Blood. 1995;86(10):3979–86.

  3. Sorely JS, Shea TC. Prevention of infections in bone marrow transplant recipients. Infect Dis Clin North Am. 1997;11(2):459–77. doi: 10.1016/s0891-5520(05)70365-2.

  4. Massaro KSR, Costa SF, Leone C, Chamone DAF. Procalcitonin (PCT) and C-reactive Protein (CRP) as severe systemic infection markers in febrile neutropenic adults. BMC Infect Dis. 2007;7(1). doi: 10.1186/1471-2334-7-137.

  5. Саржевский В.О., Дубинина Ю.Н., Мельниченко В.Я. Диагностическое и прогностическое значение биохимических маркеров инфекционных осложнений высокодозной химиотерапии с аутологичной трансплантацией гемопоэтических стволовых клеток при злокачественных лимфопролиферативных заболеваниях. Клиническая онкогематология. 2017;10(1):113–9. doi: 10.21320/2500-2139-2017-10-1-113-119.

    [Sarzhevskii VO, Dubinina YuN, Mel’nichenko VYa. Diagnostic and Prognostic Value of Biochemical Markers of Infectious Complications of High-Dose Therapy with Autologous Hematopoietic Stem Cell Transplantation in Malignant Lymphoproliferative Diseases. Clinical oncohematology. 2017;10(1):113–9. doi: 10.21320/2500-2139-2017-10-1-113-119. (In Russ)]

  6. Zhang W, Zhao Q, Huang H. Febrile neutropenic infection occurred in cancer patients undergoing autologous peripheral blood stem cell transplantation. Transplant Proc. 2015;47(2):523–7. doi: 10.1016/j.transproceed.2015.01.013.

  7. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065–71. doi: 10.1016/s0140-6736(02)08938-9.

  8. Krishnamani K, Gandhi LV, Sadashivudu G, et al. Epedimiologic, clinical profile and factors affecting the outcome in febrile neutropenia. South Asian J Cancer. 2017;6(1):25–7. doi: 10.4103/2278-330X.202565.

  9. Bates DW, Sands K, Miller E, et al. Predicting bacteremia in patients with sepsis syndrome. Academic Medical Center Consortium Sepsis Project Working Group. J Infect Dis. 1997;176(6):1538–51. doi: 10.1086/514153.

  10. Klastersky J, de Naurois J, Rolston K, et al. Management of Febrile Neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(Suppl 5):v111–v118. doi: 10.1093/annonc/mdw325.

  11. Homsi J, Walsh D, Panta R, et al. Infectious complications of advanced cancer. Support Care Cancer. 2000;8(6):487–92.

  12. Zembower TR. Epidemiology of infections in cancer patients. Cancer Treat Res. 2014;161:43–89. doi: 10.1007/978-3-319-04220-6_2.

  13. European Medicines Agency. Guideline on clinical evaluation of diagnostic agents. Available from: (accessed 30.07.2019).

  14. Павлушкина Л.В., Черневская Е.А., Дмитриева И.Б., Белобородова Н.В. Биомаркеры в клинической практике. Поликлиника. 2013;3:10–4.

    [Pavlushkina LV, Chernevskaya EA, Dmitrieva IB, Beloborodova NV. Biomarkers in clinical practice. Poliklinika. 2013;3:10–4. (In Russ)]

  15. Sbrana A, Torchio M, Comolli G, et al. Use of procalcitonin in clinical oncology: a literature review. New Microbiol. 2016;39(3):174–80.

  16. Pierrakos C, Vincent JV. Sepsis biomarkers: a review. Crit Care. 2010;14(1):R15. doi: 10.1186/cc8872.

  17. Kustan P, Horvath-Szalai Z, Muhl D. Nonconventional Markers of Sepsis. 2017;28(2):122–33.

  18. Colak A, Yilmaz C, Toprak B, Aktogu S. Procalcitonin and Crp as biomarkers in discrimination of community-acquired pneumonia and exacerbation of COPD. J Med Biochem. 2017;36:122–6. doi: 10.1515/jomb-2017-0011.

  19. Gao LQ, Liu XH, Zhang DH, et al. Early diagnosis of bacterial infection in patients with septicopyemia by laboratory analysis of PCT, CRP and IL-6. Exp Ther Med. 2017;13(6):3479–83. doi: 10.3892/etm.2017.4417.

  20. Povoa P, Coelho L, Almeida, et al. Early identification of intensive care unit-acquired infections with daily monitoring of C-reactive protein: a prospective observational study. Crit Care. 2006;10(2):R63. doi: 10.1186/cc4892.

  21. Morley JJ, Kushner I. Serum C-reactive protein levels in disease. Ann NY Acad Sci. 1982;389:(1):406–18. doi: 10.1111/j.1749-6632.1982.tb22153.x.

  22. Palmiere C, Augsburger M. Markers for sepsis diagnosis in the forensic setting: state of the art. Croat Med J. 2014;55(2):103–14. doi: 10.3325/cmj.2014.55.103.

  23. Meisner M, Tschaikowsky K, Palmers T. Procalcitonin and CRP in septic shock: Inflammatory parameters with different kinetics. Intens Care Med. 1996;22(S1):s13. doi: 10.1007/BF01921187.

  24. Samraj RS, Zingarelli B, Wong HR. Role of biomarkers in sepsis care. Shock. 2013;40(5):358–65. doi: 10.1097/Shk.0b013e3182a66bd6.

  25. Fujita MQ, Zhu B-L, Ishida K, et al. Serum C-reactive protein levels in postmortem blood – an analysis with special reference to the cause of death and survival time. Forensic Sci Int. 2002;130(2–3):160–6. doi: 10.1016/S0379-0738(02)00381-X.

  26. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805–12. doi: 10.1172/jci18921.

  27. Duzenli KD, Ozdemir ZC, Bor O. Evaluation of febrile neutropenic attacks of pediatric hematology-oncology patients. Turk Pediatr Ars. 2017;52(4):213–20. doi: 10.5152/TurkPediatriArs.2017.5312.

  28. Pineda-Roman M, Barlogie B, Tricot G, et al. High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients. Cancer. 2008;112(8):1754–64. doi: 10.1002/cncr.23327.

  29. Kollu V, Mott SL, Khan R, et al. C-Reactive Protein Monitoring Predicts Neutropenic Fever Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Cureus. 2018;10(7):e2945. doi: 10.7759/cureus.2945.

  30. Ortega M, Rovira M, Almela M, et al. Measurement of C-reactive protein in adults with febrile neutropenia after hematopoietic cell transplantation. Bone Marrow Transplant. 2004;33(7):741–4. doi: 10.1038/sj.bmt.1704409.

  31. Schots R, Kaufman L, Van Riet I, et al. Monitoring of C-reactive protein after allogeneic bone marrow transplantation identifies patients at risk of severe transplant-related complications and mortality. Bone Marrow Transplant. 1998;22(1):79–85. doi: 10.1038/sj.bmt.1701286.

  32. Sato M, Nakasone H, Wada H, et al. Prediction of infectious events by the high-sensitivity C-reactive protein level before autologous hematopoietic cell transplantation for lymphoma and multiple myeloma. Transplant Infect Dis. 2013;15(4):E169–E171. doi: 10.1111/tid.12102.

  33. Massaro K, Costa SF. Role of Biomarkers as Predictors of Infection and Death in Neutropenic Febrile Patients after Hematopoietic Stem Cell Transplantation. Mediterr J Hematol Infect Dis. 2015;7(1):e2015059. doi: 10.4084/MJHID.2015.059.

  34. Sato M, Nakasone H, Oshima K, et al. Prediction of transplant-related complications by C-reactive protein levels before hematopoietic SCT. Bone Marrow Transplant. 2013;48(5):698–702. doi: 10.1038/bmt.2012.193.

  35. Pavlu J, Kew AK, Taylor-Roberts B, et al. Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. Blood. 2010;115(2):4018–20. doi: 10.1182/blood-2010-01-263624.

  36. Wang XS, Shi Q, Shah ND, et al. Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation. Clin Cancer Res. 2014;20(5):1366–74. doi: 10.1158/1078-0432.ccr-13-2442.

  37. Fassas AB, Miceli MH, Grazzlutti M, et al. Serial measurement of serum C-reactive protein levels can identify patients at risk for severe complications following autologous stem cell transplantation. Leuk Lymphoma. 2005;46(8):1159–61. doi: 10.1080/10428190500086121.

  38. Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6(6):664–79. doi: 10.1158/

  39. Maruna P, Nedelnikova K, Gurlich R. Physiology and genetics of procalcitonin. Physiol Res. 2000;49(Suppl 1):S57–61.

  40. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med. 2008;36(3):941–52. doi: 10.1097/CCM.0B013E318165BABB.

  41. Reinhart K, Meisner M, Brunkhorst FM. Markers for sepsis diagnosis: what is useful? Crit Care Clin. 2006;22(3):503–19. doi: 10.1016/j.ccc.2006.03.003.

  42. Picariello C, Lazzeri C, Valente S, et al. Procalcitonin in acute cardiac patients. Intern Emerg Med. 2011;6(3):245–52. doi: 10.1007/s11739-010-0462-x.

  43. Reinhart K, Bauer M, Riedelmann NC, et al. New approaches to sepsis: molecular diagnostics and biomarkers. Clin Microbiol Rev. 2012;25(4):609–34. doi: 10.1128/cmr.0001612.

  44. Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341(8844):515–8. doi: 10.1016/0140-6736(93)90277-n.

  45. Wu CW, Wu JY, Chen CK, et al. Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diagnosis of severe infection in patients with febrile neutropenia? A systematic review and meta-analysis. Support Care Cancer. 2015;23(10):2863–72. doi: 10.1007/s00520-015-2650-8.

  46. Schuttrumpf S, Binder L, Hagemann T, et al. Utility of procalcitonin concentration in the evaluation of patients with malignant diseases and elevated C-reactive protein plasma concentrations. Clin Infect Dis. 2006;43(3):468–73. doi: 10.1086/505394.

  47. Shomali W, Hachem R, Chaftari AM, et al. Can procalcitonin distinguish infectious fever from tumor-related fever in non-neutropenic cancer patients? Cancer. 2012;118(23):5823–9. doi: 10.1002/cncr.27602.

  48. Meidani M, Khorvash F, Abolghasemi H, et al. Procalcitonin and quantitative C-reactive protein role in the early diagnosis of sepsis in patients with febrile neutropenia. South Asian J Cancer. 2013;2(4):216–9. doi: 10.4103/2278-330x.119913.

  49. Ahn S, Lee YS, Lim KS, et al. Adding Procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia. Support Care Cancer. 2013;21(8):2303–8. doi: 10.1007/s00520-013-1787-6.

  50. Chaftari AM, Hachem R, Reitzel R, et al. Role of Procalcitonin and Interleukin-6 in Predicting Cancer, and Its Progression Independent of Infection. PLoS One. 2015;10(7):e0130999. doi: 10.1371/journal.pone.0130999.

  51. Jimeno A, Garcia-Velasco A, Val del O, et al. Assessment of Procalcitonin as a Diagnostic and Prognostic Marker in Patients with Solid Tumors and Febrile Neutropenia. Cancer. 2004;100(11):2462–9. doi: 10.1002/cncr.20275.

  52. Carnino L, Betteto S, Loiacono M, et al. Procalcitonin as a predictive marker of infections in chemoinduced neutropenia. J Cancer Res Clin Oncol. 2010;136(4):611–5. doi: 10.1007/s00432-009-0699-9.

  53. Diness LV, Maraldo MV, Mortensen CE, et al. Procalcitonin and C-reactive protein as markers of bacterial infection in patients with solid tumors. Dan Med J. 2014;61(12):A4984.

  54. Giamarellou H, Giamarellos-Bourboulis EJ, Repoussis P, et al. Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre study. Clin Microbiol Infect. 2004;10(7):628–33. doi: 10.1111/j.1469-0691.2004.00883.x.

  55. Persson L, Engervall P, Magnuson A, et al. Use of inflammatory markers for early detection of bacteraemia in patients with febrile neutropenia. Scand J Infect Dis. 2004;36(5):365–71. doi: 10.1080/00365540410020217.

  56. Ruokonen E, Nousiainen T, Pulkki K, et al. Procalcitonin concentrations in patients with neutropenic fever. Eur J Clin Microbiol Infect Dis. 1999;18(4):283–5. doi: 10.1007/s100960050277.

  57. Robinson JO, Lamoth F, Bally F, et al. Monitoring procalcitonin in febrile neutropenia: what is its utility for initial diagnosis of infection and reassessment in persistent fever? PLoS One. 2011;6(4):e18886. doi: 10.1371/journal.pone.0018886.

  58. Patout M, Salaun M, Brunel V, et al. Diagnostic and prognostic value of serum procalcitonin concentrations in primary lung cancers. Clin Biochem. 2014;47(18):263–7. doi: 10.1016/j.clinbiochem.2014.09.002.

  59. Scheinpflug K, Schalk E, Grabert E, et al. Procalcitonin is not useful to discriminate between infectious and noninfectious CrP elevations in patients with non-small cell lung cancer. Infect Control Hosp Epidemiol. 2015;36(9):1117–8. doi: 10.1017/ice.2015.134.

  60. Yaegashi Y, Sato N, Suzuki Y, et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother. 2005;11(5):234–8. doi: 10.1007/s10156-005-0400-4.

  61. Shirakawa K, Naitou K, Hirose J, et al. The new sepsis marker, sCD14-ST, induction mechanism in the rabbit sepsis models. Crit Care. 2010;14(Suppl 2):P19. doi: 10.1186/cc9122.

  62. Shozushima T, Takahashi G, Matsumoto N, et al. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother. 2011;17(6):764–9. doi: 10.1007/s10156-011-0254-x.

  63. Endo S, Suzuki Y, Takahashi G, et al. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. J Infect Chemother. 2012;18(6):891–7. doi: 10.1007/s10156-012-0435-2.

  64. Urbonas V, Eidukaite A, Tamuliene I. The predictive value of soluble biomarkers (CD14 subtype, interleukin-2 receptor, human leucocyte antigen-G) and procalcitonin in the detection of bacteremia and sepsis in pediatric oncology patients with chemotherapy-induced febrile neutropenia. Cytokine. 2013;62(1):34–7. doi: 10.1016/j.cyto.2013.02.030.

  65. Olad E, Sedighi I, Mehrvar A, et al. Presepsin (scd14) as a marker of serious bacterial infections in chemotherapy induced severe neutropenia. Iran J Pediatr. 2014;24(6):715–22.

  66. Korpelainen S, Intke C, Hamalainen S, et al. Soluble CD14 as a Diagnostic and Prognostic Biomarker in Hematological Patients with Febrile Neutropenia. Dis Mark. 2017;2017:1–8. doi: 10.1155/2017/9805609.

  67. Koh H, Aimoto M, Katayama T, et al. Diagnostic value of levels of presepsin (soluble CD14-subtype) in febrile neutropenia in patients with hematological disorders. J Infect Chemother. 2016;22(7):466–71. doi: 10.1016/j.jiac.2016.04.002.

  68. Stoma I, Karpov I, Uss A, et al. Diagnostic value of sepsis biomarkers in hematopoietic stem cell transplant recipients in a condition of high prevalence of gram-negative pathogens. Hematol Oncol Stem Cell Ther. 2017;10(1):15–21. doi: 10.1016/j.hemonc.2016.09.002.

  69. Ebisawa K, Koya J, Nakazaki K, et al. Usefulness of presepsin for early detection of infections in patients with hematologic disorders. Clin Chim Acta. 2018;486:374–80. doi: 10.1016/j.cca.2018.08.032.

Case of Pneumocystis Pneumonia after High-Dose Chemotherapy with Autologous Hematopoietic Transplantation

V.O. Sarzhevskii1, V.Ya. Melnichenk1, D.S. Kolesnikova1, O.Yu. Bronov1, V.M. Sotnikov2, N.N. Smoltsova2

1 N.I. Pirogov National Medical and Surgical Centre under the Ministry of Health of the Russian Federation, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203

2 Russian Scientific Center of Roentgenoradiology under the Ministry of Health of the Russian Federation, 86 Profsoyuznaya str., Moscow, Russian Federation, 117997

For correspondence: V.O. Sarzhevskii, PhD, Associate Professor, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203; Tel: +7(495)603-72-18; e-mail:

For citation: Sarzhevskii V.O., Mel’nichenko V.Ya., Kolesnikova D.S., Bronov O.Yu., Sotnikov V.M., Smol’tsova N.N. Case of Pneumocystis Pneumonia after High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. Klin. Onkogematol. 2014; 7(4): 583–586 (In Russ.).


Pneumocystis pneumonia is a rare complication of a high-dose chemotherapy and autologous bone marrow/peripheral hematopoietic stem cells transplantation in patients with hematological malignances. The absence of typical clinical symptoms and the probability of a lethal outcome require a special approach to this problem. A brief review of literature and presented clinical case give an idea of clinical manifestations, course, diagnostic approaches, prevention, and treatment of pneumocystis pneumonia in this category of patients.

Keywords: autologous bone marrow transplantation, high-dose chemotherapy, pneumocystis pneumonia

Accepted: September 19, 2014

Read in PDF (RUS)pdficon


  1. Walzer P.D., Perl D.P., Krogstad D.J. et al. Pneumocystis carinii pneumonia in the United States: epidemiologic, diagnostic, and clinical features. Natl. Cancer Inst. Monogr. 1976; 43: 55–63.
  2. Green H., Paul M., Vidal L. et al. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and metaanalysis of randomized controlled trials. Mayo Clin. Proc. 2007; 82(9): 1052–9.
  3. Colby C., McAfee S., Sackstein R. et al. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/ sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999; 24(8): 897–902.
  4. Sattler F.R., Cowan R., Nielsen D.M. et al. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Ann. Intern. Med. 1988; 109(4): 280–7.
  5. Hughes W., Leoung G., Kramer F. et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N. Engl. J. Med. 1993; 328(21): 1521–7.
  6. Metzner B., Gruneisl R., Gebauer W. et al. Late infectious complications after high-dose therapy and autologous blood stem cell transplantation. Med. Klin. (Munich) 2002; 97(11): 650–8.
  7. Decaudin D., Brousse N., Brice P. et al. Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study. Bone Marrow Transplant. 2000; 25(3): 251–6.
  8. Chen C.S., Boeckh M., Seidel K. Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003; 32(5): 515–22.
  9. Chuu W.M., Catlett J.P., Perry D.J. Concurrent Pneumocystis carinii and cytomegalovirus pneumonia after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999; 23(10): 1087–9.
  10. Kato H., Yamamoto K., Taji H. et al. Interstitial pneumonia after autologous hematopoietic stem cell transplantation in B-cell non-Hodgkin lymphoma. Clin. Lymphoma Myeloma Leuk. 2011; 11(6): 483–9.
  11. Munker R., Lazarus H.M., Atkinson K. The BMT Data Book, 2nd ed. Cambridge University Press, 2009: 245.

Gastrointestinal Complications after High-Dose Chemotherapy and Autologous Bone Marrow Transplantation in Oncohematological Patients

V.O. Sarzhevskiy, E.G. Smirnova, V.Yа. Melnichenko

N.I. Pirogov National Medical and Surgical Centre of RF MH, Moscow, Russian Federation

For citation: Sarzhevskiy V.O., Smirnova E.G., Mel’nichenko V.Ya. Gastrointestinal Complications after High-Dose Chemotherapy and Autologous Bone Marrow Transplantation in Oncohematological Patients. Klin. onkogematol. 2014; 7(3): 343–53 (In Russ.).


Different gastrointestinal disorders with different degrees of severity are diagnosed in almost all oncohematological patients receiving the high-dose chemotherapy (HDC) with autologous bone marrow transplantation (transplantation of peripheral hematopoietic stem cells). The mentioned disorders (mucositis) significantly impair the quality of life, promote the development of infectious complications, and, in some cases, can cause a lethal outcome. Authors emphasize the importance of GIT disorders due to HDC with autologous bone marrow transplantation, present etiological and pathogenetic factors of mucosites and give a detailed description of the clinical evaluation, test methods, prevention and treatment of such transplantation complications in oncohematological patients.

Keywords: high dose chemotherapy, autologous bone marrow transplantation, mucositis.

Address correspondence to:

Accepted: May 26, 2014

Read in PDF  (RUS)pdficon


  1. Damon L., Rugo H., Tolaney S. et al. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim. Biol. Blood Marrow Transplant. 2006; 12(3): 316–24.
  2. Bishton M.J., Lush R.J., Byrne J.L. et al. Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. Br. J. Haematol. 2007; 136(5): 752–61.
  3. Milone G., Leotta S., Battiato K. et al. Intermediate dose etoposide plus G-CSF 16 g/kg is more effective than cyclophosphamide 4 g/m(2) plus G-CSF 10 g/kg in PBSC mobilization of lymphoma patients. Leuk. Lymphoma 2007; 48(10): 1950–60.
  4. Lu H., Li J.Y., Ge Z. et al. High-dose etoposide with granulocyte colonystimulating factor for mobilization of autologous peripheral blood stem/progenitor cells in patients with hematologic malignancies. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006; 14(2): 397–9.
  5. Bolwell B.J., Kalaycio M., Sobecks R. et al. A multivariable analysis of factors influencing mucositis after autologous progenitor cell transplantation. Bone Marrow Transplant. 2002; 30(9): 587–91.
  6. Grazziutti M.L., Dong L., Miceli M.H. et al. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant. 2006; 38(7): 501–6.
  7. Blijlevens N., Schwenkglenks M., Bacon P. et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy—European Blood and Marrow Transplantation Mucositis Advisory Group. J. Clin. Oncol. 2008; 26(9): 1519–25.
  8. Blanes M., Lahuerta J.J., Gonzalez J.D. et al. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach. Biol. Blood Marrow Transplant. 2013; 19(1): 69–74.
  9. Jantunen E., Kuittinen T., Nousiainen T. et al. BEAC or BEAM for high-dose therapy in patients with non-Hodgkin’s lymphoma? A single centre analysis on toxicity and efficacy. Leuk. Lymphoma 2003; 44(7): 1151–8.
  10. Jo J.C., Kang B.W., Jang G. et al. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: comparative analysis of efficacy and toxicity. Ann. Hematol. 2008; 87(1): 43–8.
  11. Kim J.E., Lee D.H., Yoo C. et al. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: a single center comparative analysis of efficacy and toxicity. Leuk. Res. 2011; 35(2): 183–7.
  12. Dean R.M., Pohlman B., Sweetenham J.W. et al. Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide. Br. J. Haematol. 2010; 148(2): 226–34.
  13. Spielberger R., Stiff P., Bensinger W. et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N. Engl. J. Med. 2004; 351(25): 2590–8.
  14. Krishnan A., Palmer J.M., Tsai N.C. et al. Matched-cohort analysis of autologous hematopoietic cell transplantation with radioimmunotherapy versus total body irradiation-based conditioning for poor-risk diffuse large cell lymphoma. Biol. Blood Marrow Transplant. 2012; 18(3): 441–50.
  15. Paris F., Fuks Z., Kang A. et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 2001; 293: 293–7.
  16. Wearing H.J., Sherratt J.A. Keratinocyte growth factor signaling: a mathematical model of dermalepidermal interaction in epidermal wound healing. Math. Biosci. 2000; 165: 41–62.
  17. Sonis S. Pathobiology of oral mucositis: novel insights and opportunities. J. Supp. Oncol. 2007; 5: 3–11.
  18. Wardley A.M., Jayson G.C., Swindell R. et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br. J. Haematol. 2000; 110(2): 292–9.
  19. Vokurka S., Bystricka E., Koza V. et al. Higher incidence of chemotherapy induced oral mucositis in females: a supplement of multivariate analysis to a randomized multicentre study. Supp. Care Cancer 2006; 14(9): 974–6.
  20. Hahn T., Zhelnova E., Sucheston L. et al. A deletion polymorphism in glutathione-S-transferase mu (GSTM1) and/or theta (GSTT1) is associated with an increased risk of toxicity after autologous blood and marrow transplantation. Biol. Blood Marrow Transplant. 2010; 16(6): 801–8.
  21. Grazziutti M.L., Dong L., Miceli M.H. et al. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant. 2006; 38(7): 501–6.
  22. Krishna S.G., Zhao W., Grazziutti M.L. et al. Incidence and risk factors for lower alimentary tract mucositis after 1529 courses of chemotherapy in a homogenous population of oncology patients: clinical and research implications. Cancer 2011; 117(3): 648–55.
  23. Bensinger W., Schubert M., Ang K.K. et al. NCCN Task Force Report: prevention and management of mucositis in cancer care. J. Natl. Compr. Cancer Netw. 2008; 6(Suppl. 1): S1–21.
  24. Atkinson K., Champlin R., Ritz J. et al. (eds.) Clinical Bone Marrow and Blood Stem Cell Transplantation, 3rd edn. Cambridge University Press, 2004: 276–7.
  25. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Published August 9, 2006. Available at:
  26. Forbes G.M., Rule S.A., Herrmann R.P. et al. A prospective study of screening upper gastrointestinal (GI) endoscopy prior to and after bone marrow transplantation (BMT). Aust. N. Z. J. Med. 1995; 25(1): 32–6.
  27. Vishny M.L., Blades E.W., Creger R.J. et al. Role of upper endoscopy in evaluation of upper gastrointestinal symptoms in patients undergoing bone marrow transplantation. Cancer Invest. 1994; 12(4): 384–9.
  28. Tsirigotis P., Triantafyllou K., Girkas K. et al. Keratinocyte growth factor is effective in the prevention of intestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study. Bone Marrow Transplant. 2008; 42(5): 337–43.
  29. Avivi I., Avraham S., Koren-Michowitz M. et al. Oral integrity and salivary profile in myeloma patients undergoing high-dose therapy followed by autologous SCT. Bone Marrow Transplant. 2009; 43(10): 801–6.
  30. Blijlevens N.M., Donnelly J.P., de Pauw B.E. Prospective evaluation of gut mucosal barrier injury following various myeloablative regimens for haematopoietic stem cell transplant. Bone Marrow Transplant. 2005; 35(7): 707–11.
  31. Johansson J.E., Brune M., Ekman T. The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning. Bone Marrow Transplant. 2001; 28(8): 737–42.
  32. van Kraaij M.G., Dekker A.W., Verdonck L.F. et al. Infectious gastroenteritis: an uncommon cause of diarrhoea in adult allogeneic and autologous stem cell transplant recipients. Bone Marrow Transplant. 2000; 26(3): 299–303.
  33. Chakrabarti S., Collingham K.E., Stevens R.H. et al. Isolation of viruses from stools in stem cell transplant recipients: a prospective surveillance study. Bone Marrow Transplant. 2000; 25(3): 277–82.
  34. Davila M.L. Neutropenic enterocolitis. Curr. Opin. Gastroenterol. 2006; 22(1): 44–7.
  35. Ullery B.W., Pieracci F.M., Rodney J.R. et al. Neutropenic enterocolitis. Surg. Infect. (Larchmt.) 2009; 10(3): 307–14.
  36. Arango J.I., Restrepo A., Schneider D.L. et al. Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant. 2006; 37(5): 517–21.
  37. Tomblyn M., Gordon L., Singhal S. et al. Rarity of toxigenic Clostridium difficile infections after hematopoietic stem cell transplantation: implications for symptomatic management of diarrhea. Bone Marrow Transplant. 2002; 30(8): 517–9.
  38. Avery R., Pohlman B., Adal K. et al. High prevalence of diarrhea but infrequency of documented Clostridium difficile in autologous peripheral blood progenitor cell transplant recipients. Bone Marrow Transplant. 2000; 25(1): 67–9.
  39. Ramsey D.J., Schey S.A. Cytomegalovirus colitis after autologous transplantation for multiple myeloma. Br. J. Haematol. 2000; 110(4): 894–6.
  40. Cohen Y., Paltiel O., Amir G. et al. Unusual cytomegalovirus complications after autologous stem cell transplantation for large B cell lymphoma: massive gastrointestinal hemorrhage followed by a communicating hydrocephalus. Bone Marrow Transplant. 2002; 29(8): 715–6.
  41. MASCC/ISOO evidence-based clinical practice guidelines for mucositis secondary to cancer therapy.
  42. Yamagata K., Arai C., Sasaki H. et al. The effect of oral management on the severity of oral mucositis during hematopoietic SCT. Bone Marrow Transplant. 2012; 47(5): 725–30. doi: 10.1038/bmt.2011.171.
  43. Stiff P.J., Emmanouilides C., Bensinger W.I. et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J. Clin. Oncol. 2006; 24(33): 5186–93.
  44. Abidi M.H., Agarwal R., Tageja N. et al. A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function. Biol. Blood Marrow Transplant. 2013; 19(1): 56–61.
  45. Abidi M.H., Agarwal R., Ayash L. et al. Melphalan 180 mg/m2 can be safely administered as conditioning regimen before an autologous stem cell transplantation (ASCT) in multiple myeloma patients with creatinine clearance 60 mL/min/1.73 m2 or lower with use of palifermin for cytoprotection: results of a phase I trial. Biol. Blood Marrow Transplant. 2012; 18(9): 1455–61.
  46. Lilleby K., Garcia P., Gooley T. et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 2006; 37(11): 1031–5.
  47. Salvador P., Azusano C., Wang L. et al. A pilot randomized controlled trial of an oral care intervention to reduce mucositis severity in stem cell transplant patients. J. Pain Sympt. Manage 2012; 44(1): 64–73.
  48. Vokurka S., Bystricka E., Scudlova J. et al. The risk factors for oral mucositis and the effect of cryotherapy in patients after the BEAM and HD-l-PAM 200 mg/m(2) autologous hematopoietic stem cell transplantation. Eur. J. Oncol. Nurs. 2011; 15(5): 508–12.
  49. Antunes H.S., de Azevedo A.M., da Silva Bouzas L.F. et al. Low-power laser in the prevention of induced oral mucositis in bone marrow transplantation patients: a randomized trial. Blood 2007; 109(5): 2250–5.
  50. Silva G.B., Mendonca E.F., Bariani C. et al. The prevention of induced oral mucositis with low-level laser therapy in bone marrow transplantation patients: a randomized clinical trial. Photomed. Laser Surg. 2011; 29(1): 27–31.
  51. Schubert M.M., Eduardo F.P., Guthrie K.A. et al. A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Supp. Care Cancer 2007; 15(10): 1145–54.
  52. Spencer A., Horvath N., Gibson J. et al. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant. 2005; 35(10): 971–7.
  53. Gabriel D.A., Shea T.C., Serody J.S. et al. Cytoprotection by amifostine during autologous stem cell transplantation for advanced refractory hematologic malignancies. Biol. Blood Marrow Transplant. 2005; 11(12): 1022–30.
  54. Phillips G.L. 2nd, Bernstein S.H., Liesveld J.L. et al. A Phase I trial: dose escalation of melphalan in the ‘BEAM’ regimen using amifostine cytoprotection. Biol. Blood Marrow Transplant. 2011; 17(7): 1033–42.
  55. Wasko-Grabowska A., Rzepecki P., Oborska S. et al. Efficiency of supersaturated calcium phosphate mouth rinse treatment in patients receiving highdose melphalan or BEAM prior to autologous blood stem cell transplantation: a single-center experience. Transplant. Proc. 2011; 43(8): 3111–3.
  56. Васильева В.А., Кузьмина Л.А., Клясова Г.А. и др. Опыт применения фосфата кальция у больных после высокодозной полихимиотерапии и трансплантации гемопоэтических стволовых клеток. Гематол. и транс- фузиол. 2012; 57(3): 11–3. [Vasil’eva V.A., Kuz’mina L.A., Klyasova G.A. et al. An experience in the use of potassium phosphate in patients after the high-dose polychemotherapy and transplantation of hemopetic stem cells. Gematol. i transfuziol. 2012; 57(3): 11–3. (In Russ.)]
  57. Oblon D.J., Paul S.R., Oblon M.B. et al. Propantheline protects the oral mucosa after high-dose ifosfamide, carboplatin, etoposide and autologous stem cell transplantation. Bone Marrow Transplant. 1997; 20(11): 961–3.
  58. Lockhart P.B., Brennan M.T., Kent M.L. et al. Randomized controlled trial of pilocarpine hydrochloride for the moderation of oral mucositis during autologous blood stem cell transplantation. Bone Marrow Transplant. 2005; 35(7): 713–20.
  59. Costa L.J., Micallef I.N., Inwards D.J. et al. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma. Br. J. Haematol. 2008; 143(2): 268–73.
  60. Eisen D., Essell J., Broun E.R. et al. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. Bone Marrow Transplant. 2003; 31(1): 51–5.
  61. Lovenich H., Schutt-Gerowitt H., Keulertz C. et al. Failure of anti-infective mouth rinses and concomitant antibiotic prophylaxis to decrease oral mucosal colonization in autologous stem cell transplantation. Bone Marrow Transplant. 2005; 35(10): 997–1001.
  62. Strupp C., Sudhoff T., Germing U. et al. Transdermal fentanyl during high-dose chemotherapy and autologous stem cell support. Oncol. Rep. 2000; 7(3): 659–61. 63. Pinana J.L., Montesinos P., Martino R. et al. Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients. Ann. Hematol. 2014; 93(2): 299–307